<p>RBO &amp; Co. LLC 在最近向證券交易委員會提交的文件中表示，在第一季度將其在強生（NYSE:JNJ - 免費報告）的持股增加了 1.2%。該基金在本季度購買了額外的 2,605 股後，持有該公司 216,179 股股票。強生大約佔 RBO &amp; Co. LLC 持股的 5.7%，是其第三大持股。RBO &amp; Co. LLC 在強生的持股在最近一個季度末價值為 35,851,000 美元。</p>
<ul>
<li>JNJ 股票的上漲信號顯示對新增長路徑的信心</li>
</ul>
<p>其他幾家對沖基金最近也調整了對 JNJ 的持股。Brighton Jones LLC 在第四季度將其在強生股票中的持股增加了 13.9%。Brighton Jones LLC 現在持有 51,876 股該公司的股票，價值 7,502,000 美元，此前在上個季度購買了額外的 6,332 股。Hudson Value Partners LLC 在第四季度將其在強生的持股增加了 2.5%。Hudson Value Partners LLC 現在持有 41,403 股該公司的股票，價值 5,648,000 美元，此前在上個季度收購了額外的 1,022 股。Topsail Wealth Management LLC 在第四季度購買了強生的新頭寸，價值約為 369,000 美元。Voya Financial Advisors Inc.在第四季度將其在強生的持股增加了 6.0%。Voya Financial Advisors Inc.現在持有 4,998 股該公司的股票，價值 716,000 美元，此前在上個季度收購了額外的 282 股。最後，Cheviot Value Management LLC 在第四季度將其在強生的持股增加了 9.8%。Cheviot Value Management LLC 現在持有 155,318 股該公司的股票，價值 22,462,000 美元，此前在上個季度收購了額外的 13,823 股。機構投資者持有該公司 69.55% 的股票。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<h2>強生股票表現</h2>
<p>強生（JNJ）股票週五開盤價為 179.0980 美元。該公司的 50 日簡單移動平均為 163.48 美元，200 日簡單移動平均為 159.23 美元。該公司的速動比率為 0.76，流動比率為 1.01，債務與股本比率為 0.50。該公司的市值為 4313.3 億美元，市盈率為 19.15，市盈增長比率為 2.28，貝塔值為 0.41。強生的 12 個月低點為 140.68 美元，12 個月高點為 181.16 美元。</p>
<ul>
<li>3 只強勁盈利的高分紅股票</li>
</ul>
<p>強生（NYSE:JNJ - 獲取免費報告）最近於 7 月 16 日（星期三）公佈了季度財報。該公司報告本季度每股收益為 2.77 美元，超出分析師一致預期的 2.68 美元，超出幅度為 0.09 美元。該公司本季度的收入為 237.4 億美元，而分析師預期為 228.5 億美元。強生的淨利潤率為 25.00%，股本回報率為 32.49%。該公司本季度的收入同比增長 5.8%。在去年同期，該公司每股收益為 2.82 美元。強生已將其 2025 財年的指引設定為 10.800-10.900 美元的每股收益。股票研究分析師預計強生在當前財年將發佈 10.58 美元的每股收益。</p>
<h2>強生宣佈分紅</h2>
<p>該公司還最近披露了季度分紅，將於 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股東將獲得 1.30 美元的分紅。這相當於年化分紅為 5.20 美元，分紅收益率為 2.9%。該分紅的除息日為 8 月 26 日（星期二）。強生的派息比率目前為 55.61%。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>擔心反彈減弱？考慮這 3 只分紅股票</li>
</ul>
<p>幾位研究分析師最近對 JNJ 股票發表了看法。Guggenheim 在 7 月 17 日（星期四）的研究報告中重申了對強生的 “中性” 評級，並將目標價設定為 167.00 美元（之前為 164.00 美元）。Wall Street Zen 在 7 月 18 日（星期五）將強生的評級從 “強力買入” 下調至 “買入”。Leerink Partners 在 5 月 13 日（星期二）的研究報告中將強生的評級從 “跑贏大盤” 下調至 “市場表現”，並將該股票的目標價從 169.00 美元下調至 153.00 美元。瑞銀集團在 7 月 17 日（星期四）將強生的目標價從 180.00 美元上調至 190.00 美元，並給予該股票 “買入” 評級。最後，加拿大皇家銀行在 7 月 17 日（星期四）將強生的目標價從 181.00 美元上調至 185.00 美元，並給予該股票 “跑贏大盤” 評級。兩位研究分析師對該股票給予了 “強力買入” 評級，九位給予了 “買入” 評級，九位給予了 “持有” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 176.29 美元。</p>
<p><strong>閲讀我們關於 JNJ 的最新股票報告</strong></p>
<h2>關於強生</h2>
<p>（免費報告）</p>
<p>強生是一家控股公司，專注於醫療領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>為什麼理解期權交易量對成功的期權交易至關重要</li>
<li>MarketBeat 周評 – 08/18 - 08/22</li>
<li>內部人士出售解釋：它能否影響你的投資選擇？</li>
<li>皇家加勒比的盈利超出預期，推動強勁的 2025 年展望</li>
<li>澳大利亞證券交易所（ASX）是什麼</li>
<li>Alphabet 的突破潛力：從落後者到 AI 領導者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在強生嗎？</h2>
<p>在考慮強生之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
<p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>RBO & Co. LLC 在第一季度將其在強生（NYSE: JNJ）的持股增加了 1.2%，目前持有 216,179 股，價值 3585 萬美元。其他對沖基金也增加了在 JNJ 的持倉。該股票開盤價為 179.10 美元，市值為 4313.3 億美元，市盈率為 19.15。強生報告第二季度每股收益為 2.77 美元，超出預期，並宣佈季度股息為 1.30 美元，收益率為 2.9%。分析師的評級意見不一，目標價格範圍從 153 美元到 190 美元</p>

<p>RBO &amp; Co. LLC grew its holdings in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 1.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 216,179 shares of the company's stock after purchasing an additional 2,605 shares during the quarter. Johnson &amp; Johnson makes up approximately 5.7% of RBO &amp; Co. LLC's holdings, making the stock its 3rd biggest holding. RBO &amp; Co. LLC's holdings in Johnson &amp; Johnson were worth $35,851,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>RBO &amp; Co. LLC 在最近向證券交易委員會提交的文件中表示，在第一季度將其在強生（NYSE:JNJ - 免費報告）的持股增加了 1.2%。該基金在本季度購買了額外的 2,605 股後，持有該公司 216,179 股股票。強生大約佔 RBO &amp; Co. LLC 持股的 5.7%，是其第三大持股。RBO &amp; Co. LLC 在強生的持股在最近一個季度末價值為 35,851,000 美元。</p>
</div><ul>
<li>JNJ Stock Surge Signals Confidence in New Growth Path</li>
</ul>
<div class="lb-trans"><ul>
<li>JNJ 股票的上漲信號顯示對新增長路徑的信心</li>
</ul>
</div><p>Several other hedge funds also recently modified their holdings of JNJ. Brighton Jones LLC boosted its stake in shares of Johnson &amp; Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC boosted its stake in Johnson &amp; Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Topsail Wealth Management LLC bought a new position in Johnson &amp; Johnson during the 4th quarter worth approximately $369,000. Voya Financial Advisors Inc. boosted its stake in Johnson &amp; Johnson by 6.0% during the 4th quarter. Voya Financial Advisors Inc. now owns 4,998 shares of the company's stock worth $716,000 after acquiring an additional 282 shares during the last quarter. Finally, Cheviot Value Management LLC boosted its stake in Johnson &amp; Johnson by 9.8% during the 4th quarter. Cheviot Value Management LLC now owns 155,318 shares of the company's stock worth $22,462,000 after acquiring an additional 13,823 shares during the last quarter. Institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也調整了對 JNJ 的持股。Brighton Jones LLC 在第四季度將其在強生股票中的持股增加了 13.9%。Brighton Jones LLC 現在持有 51,876 股該公司的股票，價值 7,502,000 美元，此前在上個季度購買了額外的 6,332 股。Hudson Value Partners LLC 在第四季度將其在強生的持股增加了 2.5%。Hudson Value Partners LLC 現在持有 41,403 股該公司的股票，價值 5,648,000 美元，此前在上個季度收購了額外的 1,022 股。Topsail Wealth Management LLC 在第四季度購買了強生的新頭寸，價值約為 369,000 美元。Voya Financial Advisors Inc.在第四季度將其在強生的持股增加了 6.0%。Voya Financial Advisors Inc.現在持有 4,998 股該公司的股票，價值 716,000 美元，此前在上個季度收購了額外的 282 股。最後，Cheviot Value Management LLC 在第四季度將其在強生的持股增加了 9.8%。Cheviot Value Management LLC 現在持有 155,318 股該公司的股票，價值 22,462,000 美元，此前在上個季度收購了額外的 13,823 股。機構投資者持有該公司 69.55% 的股票。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>強生股票表現</h2>
</div><p>Shares of JNJ stock opened at $179.0980 on Friday. The company's fifty day simple moving average is $163.48 and its 200-day simple moving average is $159.23. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $431.33 billion, a PE ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41. Johnson &amp; Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.</p>
<div class="lb-trans"><p>強生（JNJ）股票週五開盤價為 179.0980 美元。該公司的 50 日簡單移動平均為 163.48 美元，200 日簡單移動平均為 159.23 美元。該公司的速動比率為 0.76，流動比率為 1.01，債務與股本比率為 0.50。該公司的市值為 4313.3 億美元，市盈率為 19.15，市盈增長比率為 2.28，貝塔值為 0.41。強生的 12 個月低點為 140.68 美元，12 個月高點為 181.16 美元。</p>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只強勁盈利的高分紅股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.82 earnings per share. Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）最近於 7 月 16 日（星期三）公佈了季度財報。該公司報告本季度每股收益為 2.77 美元，超出分析師一致預期的 2.68 美元，超出幅度為 0.09 美元。該公司本季度的收入為 237.4 億美元，而分析師預期為 228.5 億美元。強生的淨利潤率為 25.00%，股本回報率為 32.49%。該公司本季度的收入同比增長 5.8%。在去年同期，該公司每股收益為 2.82 美元。強生已將其 2025 財年的指引設定為 10.800-10.900 美元的每股收益。股票研究分析師預計強生在當前財年將發佈 10.58 美元的每股收益。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>強生宣佈分紅</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson &amp; Johnson's payout ratio is currently 55.61%.</p>
<div class="lb-trans"><p>該公司還最近披露了季度分紅，將於 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股東將獲得 1.30 美元的分紅。這相當於年化分紅為 5.20 美元，分紅收益率為 2.9%。該分紅的除息日為 8 月 26 日（星期二）。強生的派息比率目前為 55.61%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>擔心反彈減弱？考慮這 3 只分紅股票</li>
</ul>
</div><p>Several research analysts recently weighed in on JNJ shares. Guggenheim reissued a &#34;neutral&#34; rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson &amp; Johnson in a research note on Thursday, July 17th. Wall Street Zen lowered shares of Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Friday, July 18th. Leerink Partners lowered shares of Johnson &amp; Johnson from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and reduced their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. UBS Group lifted their price objective on shares of Johnson &amp; Johnson from $180.00 to $190.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada lifted their price objective on shares of Johnson &amp; Johnson from $181.00 to $185.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $176.29.</p>
<div class="lb-trans"><p>幾位研究分析師最近對 JNJ 股票發表了看法。Guggenheim 在 7 月 17 日（星期四）的研究報告中重申了對強生的 “中性” 評級，並將目標價設定為 167.00 美元（之前為 164.00 美元）。Wall Street Zen 在 7 月 18 日（星期五）將強生的評級從 “強力買入” 下調至 “買入”。Leerink Partners 在 5 月 13 日（星期二）的研究報告中將強生的評級從 “跑贏大盤” 下調至 “市場表現”，並將該股票的目標價從 169.00 美元下調至 153.00 美元。瑞銀集團在 7 月 17 日（星期四）將強生的目標價從 180.00 美元上調至 190.00 美元，並給予該股票 “買入” 評級。最後，加拿大皇家銀行在 7 月 17 日（星期四）將強生的目標價從 181.00 美元上調至 185.00 美元，並給予該股票 “跑贏大盤” 評級。兩位研究分析師對該股票給予了 “強力買入” 評級，九位給予了 “買入” 評級，九位給予了 “持有” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 176.29 美元。</p>
</div><p><strong>Read Our Latest Stock Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 JNJ 的最新股票報告</strong></p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>關於強生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>強生是一家控股公司，專注於醫療領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li>
<li>MarketBeat Week in Review – 08/18 - 08/22</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Royal Caribbean Earnings Beat Fuels Strong 2025 Outlook</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Alphabet’s Breakout Potential: From Laggard to AI Leader</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>為什麼理解期權交易量對成功的期權交易至關重要</li>
<li>MarketBeat 周評 – 08/18 - 08/22</li>
<li>內部人士出售解釋：它能否影響你的投資選擇？</li>
<li>皇家加勒比的盈利超出預期，推動強勁的 2025 年展望</li>
<li>澳大利亞證券交易所（ASX）是什麼</li>
<li>Alphabet 的突破潛力：從落後者到 AI 領導者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在強生嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮強生之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

RBO & Co. LLC 增加了其在強生公司$JNJ 的股票持倉